Bijal D. Shah, MD

Shah explained that the trial is unique due to its inclusion of patients with MRD–positive B-ALL.

Experts discussed the ZUMA-2 clinical trial of brexucabtagene autoleucel.

The hematologists from Moffitt Cancer Center and MD Anderson Cancer Center discussed the need for collaboration between academic and community practices for patients who receive CAR T-cell therapy.

The hematologist from Moffitt Cancer Center and MD Anderson Cancer Center discussed CAR T-cell therapy and other treatment options for MCL.

The hematologist from Moffitt Cancer Center discussed the FDA approval of brexucabtagene autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.

The hematologist from Moffitt Cancer Center discussed the FDA approval of brexucabtagne autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.

The associate member in the Department of Malignant Hematology at Moffitt Cancer Center discussed results of the ZUMA-3 trial.

Eunice Wang, MD, and Bijal Shah, MD, MS, discussed unmet needs for adult patients with relapsed/refractory ALL and reflect on the current treatment landscape.

Bijal Shah, MD, MS, and Eunice Wang, MD, discussed the use of clinical endpoints like CR, CRi, and CRh as they relate to the ZUMA-3 trial of CAR T cell therapy.

The hematologist from Moffitt Cancer Center discussed the timing of treatment with chimeric antigen receptor T-cell therapy in patients with acute lymphoblastic leukemia.

Bijal Shah, MD, MS, and Eunice Wang, MD, discuss efficacy results of the ZUMA-3 trial of chimeric antigen receptor (CAR) T-cell therapy for acute lymphocytic leukemia (ALL), and review key safety data.

Eunice Wang, MD, and Bijal Shah, MD, MS, discuss the overall study design and patient population of the ZUMA-3 trial of CAR T-cell therapy in adult patients with R/R ALL.

Eunice Wang, MD, and Bijal Shah, MD, MS, discussed the use of MRD status to assess therapeutic response and guide treatment decisions in patients with relapsed/refractory ALL.  

Eunice Wang, MD and Bijal Shah, MD, MS, discuss novel agents and emerging therapeutic approaches for the treatment of acute lymphoblastic leukemia.

Bijal D. Shah, MD, discusses the progress made regarding CAR T-cell therapy and mantle cell lymphoma.

Bijal D. Shah, MD, associate professor, Department of Malignant Hematology, Moffitt Cancer Center, discusses the use of CAR T-cell therapy in patients with pediatric acute lymphoblastic leukemia (ALL).

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses the challenges of developing clinical trials for CAR T cells in mantle cell lymphoma.

Bijal D. Shah, MD, medical oncology, Moffit Cancer Center, discusses the importance of chimeric antigen receptor (CAR) T-cell therapy for patients with acute lymphoblastic leukemia (ALL).

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, comments on the toxicities associated with using chimeric antigen receptor (CAR) T-cell therapy in patients with leukemia.

Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, explains why chimeric antigen receptor (CAR) T-cell therapy has shown the most progress in acute lymphoblastic leukemia (ALL).

Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, discusses the status of chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).